.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Merck
Deloitte
Cipla
Chinese Patent Office
Daiichi Sankyo
Express Scripts
Fuji
Johnson and Johnson

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,960,564

« Back to Dashboard

Which drugs does patent 6,960,564 protect, and when does it expire?


Patent 6,960,564 protects ERAXIS and is included in one NDA.

This patent has twenty-one patent family members in seventeen countries.

Summary for Patent: 6,960,564

Title: Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Abstract:Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
Inventor(s): Milton; Nathaniel (Indianapolis, IN), Moder; Kenneth Philip (West Lafayette, IN), Sabatowski; James Lawrence (Holland, MI), Sweetana; Stephanie Ann (Bloomington, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/942,431
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
VicuronERAXISanidulafunginINJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeYTREATMENT OF FUNGAL INFECTIONS► Subscribe
VicuronERAXISanidulafunginINJECTABLE;IV (INFUSION)021632-002Nov 14, 2006RXYesYes► Subscribe► SubscribeYTREATMENT OF FUNGAL INFECTIONS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,960,564

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,709,444Echinocandin pharmaceutical formulations containing micelle-forming surfactants► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,960,564

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2250763► Subscribe
Portugal1582204► Subscribe
Japan4936595► Subscribe
Japan2002538095► Subscribe
Japan4755464► Subscribe
Japan2005325142► Subscribe
Israel145185► Subscribe
Hong Kong1074803► Subscribe
Spain2433678► Subscribe
European Patent Office1582204► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Deloitte
Chubb
Daiichi Sankyo
Johnson and Johnson
Chinese Patent Office
Farmers Insurance
Novartis
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot